DiaMedica
在场
DiaMedica 是一家在股票代码 DMAC (CA) 下上市的公司。
高管
查看带有其 13 名主要高管的组织结构图
DiaMedica 搜索最多的简介
- Rick Pauls, Director, President and Chief Executive Officer
- Richard Pilnik, Chairman of the Board
- Tanya Lewis, Director
创建提醒
跟踪 DiaMedica 的高管变动
生物技术
DiaMedica 拥有 2,332 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- March Biosciences 刚刚宣布为 28 筹款数百万美元。 (公布2024十二月3号).
- Lyell Immunopharma 已收购 ImmPACT Bio (公布2024十一月29号).
- Hopo Therapeutics 刚刚宣布为 226 筹款数百万美元。 (公布2024十一月29号).
生物技术 行业的其他推荐联系人
消息
DiaMedica 的最新新闻稿
- DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia
- DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results
- DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia
- DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference
- DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024
- DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia
- DiaMedica Therapeutics Upcoming Conference Participation
- DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results
- DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024
- DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
- View more press releases Close
通过电子邮件
